Develops therapies for cancer treatment, focusing on targeted antibody-drug conjugates and combination therapies.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancer treatment in the United States. The company's leading product candidate, Validive, is a clonidine hydrochloride mucobuccal tablet currently in Phase 2b/3 clinical trials. It aims to prevent chemoradiotherapy-induced severe oral mucositis in patients with oropharyngeal cancer. Monopar also develops Camsirubicin, a doxorubicin analog in Phase 1b trials for advanced soft tissue sarcoma treatment.
In addition to these, Monopar is advancing MNPR-101, a urokinase plasminogen activator receptor-targeted antibody intended for various cancer treatments. The company is also developing MNPR-101 RIT, a radioimmunotherapeutic derived from MNPR-101, which has potential applications in cancer and severe COVID-19 treatment. Another key project is MNPR-202, an analog of camsirubicin, designed to potentially treat cancers resistant to doxorubicin and camsirubicin.
Incorporated in 2014 and headquartered in Wilmette, Illinois, Monopar Therapeutics has established notable collaborations to enhance its research and development efforts. These include partnershis with the Grupo Español de Investigación en Sarcomas for Camsirubicin development in advanced soft tissue sarcoma patients, NorthStar Medical Radioisotopes, LLC for developing radio-immuno-therapeutics targeting severe COVID-19, and the Cancer Science Institute of Singapore to evaluate MNPR-202 and related analogs' activity in various cancer types. Through these collaborations, Monopar aims to advance its innovative cancer treatments and improve patient outcomes.